Discover Magazine on MSN4d
Triggering Cancer Cells To Self-Destruct Could Help Tumors to Shrink
Overriding the "Off Switch" Cells function through an intricate network of proteins, each designed for specific tasks like ...
The Unheralded End of China's First Generation of Naturalized Football Players
The integration of naturalized players into the Chinese national team marked a significant milestone in the nation’s football history. Initially, players like Exon, Alan, and Fernando were seen as key ...
The Brighterside of News on MSN7d
Researchers discovered how to turn on cancer’s 'kill switch'
Cells have a natural editing system that allows them to rearrange genetic instructions to create different proteins from the ...
Devdiscourse6d
Unlocking Cancer's Kryptonite: The Power of Poison Exons
Scientists reveal how cancer cells manipulate RNA splicing, increasing tumor growth. A new study introduces antisense ...
Science Daily6d
Scientists discover how to reactivate cancer's molecular 'kill switch'
Researchers have discovered that cancer cells suppress 'poison exons' -- genetic elements that act as an off switch for protein production -- in a key gene called TRA2 , promoting tumor growth. By ...
Managed Healthcare Executive3d
Promising Early Results of Investigational Duchenne Muscular Dystrophy Therapy
Avidity Biosciences Inc. says will submit an application for accelerated approval to the FDA for del-zota before the end of ...
BioSpace5d
Dyne’s Duchenne Exon Skipping Oligomer Shows ‘Differentiated’ Clinical Effect
Dyne is eyeing an accelerated approval filing for DYNE-251 in early 2026 that would pit the asset against Sarepta’s Exondys ...
ArriVent Lead Drug Candidate Shows Promise In Lung Cancer Type, Analyst Sees Over 50% Upside
B. Riley initiates coverage on ArriVent Biopharma, citing firmonertinib's potential in NSCLC. The analyst sees strong upside with a $37 price target.
Avidity Biosciences announces del-zota topline data from EXPLORE44 trial
Avidity Biosciences (RNA) announced del-zota topline data from the Phase 1/2 EXPLORE44 trial in people living with Duchenne muscular dystrophy ...
CURE12d
Gleevec Response in GIST May Be Linked to Mutational Profile
Gleevec response in GIST varies by mutational profile, with KIT-exon-11 mutation linked to better outcomes, emphasizing ...
Avidity Biosciences announces ‘positive’ data from Phase 1/2 EXPLORE44 trial
Avidity Biosciences (RNA) announced positive del-zota topline data from the Phase 1/2 EXPLORE44 trial in people living with Duchenne muscular ...
Nature3y
exon / exons
Exons are coding sections of an RNA transcript, or the DNA encoding it, that are translated into protein. Exons can be separated by intervening sections of DNA that do not code for proteins, known ...